OEP Pharma

OEP Pharma is a global pharmaceutical company with a focus on advancing pharmaceutical innovation and expanding market reach. As the U.S. headquarters of OEP Group, a TWSE-listed pharmaceutical company founded in Taiwan in 1982, OEP Pharma leverages its R&D capabilities and commercial infrastructure in Asia to develop, manufacture, and commercialize branded and generic medicines. With $200 million USD market cap and 1000 employees worldwide, OEP has a 40-year track record as a distributor of choice in Taiwan and ASEAN countries. The company's portfolio includes a growing range of generics and specialty pharma products, along with an experienced salesforce in 10 countries and distribution partners in North America. OEP also operates FDA-approved facilities specializing in complex formulations, including highly potent compounds and modified release products. In early 2021, the company expects FDA approval for its injectables facility. OEP Pharma's commitment to INTEGRITY, INNOVATION, and ACCESS underscores its efforts to drive pharmaceutical advancement.